Jacobio Pharmaceuticals Group Co., Ltd.

OTCPK:JBPH.F Stock Report

Market Cap: US$700.2m

Jacobio Pharmaceuticals Group Management

Management criteria checks 4/4

Jacobio Pharmaceuticals Group's CEO is Yinxiang Wang, appointed in Nov 2025, has a tenure of less than a year. total yearly compensation is CN¥2.90M, comprised of 94.5% salary and 5.5% bonuses, including company stock and options. directly owns 15.08% of the company’s shares, worth $105.57M. The average tenure of the management team and the board of directors is 4.4 years and 5.4 years respectively.

Key information

Yinxiang Wang

Chief executive officer

CN¥2.9m

Total compensation

CEO salary percentage94.48%
CEO tenureless than a year
CEO ownership15.1%
Management average tenure4.4yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Yinxiang Wang's remuneration changed compared to Jacobio Pharmaceuticals Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-CN¥46m

Mar 31 2025n/an/a

-CN¥101m

Dec 31 2024CN¥3mCN¥3m

-CN¥156m

Sep 30 2024n/an/a

-CN¥259m

Jun 30 2024n/an/a

-CN¥362m

Mar 31 2024n/an/a

-CN¥361m

Dec 31 2023CN¥3mCN¥3m

-CN¥359m

Sep 30 2023n/an/a

-CN¥385m

Jun 30 2023n/an/a

-CN¥410m

Mar 31 2023n/an/a

-CN¥391m

Dec 31 2022CN¥4mCN¥2m

-CN¥372m

Sep 30 2022n/an/a

-CN¥332m

Jun 30 2022n/an/a

-CN¥292m

Mar 31 2022n/an/a

-CN¥297m

Dec 31 2021CN¥4mCN¥2m

-CN¥301m

Compensation vs Market: Yinxiang's total compensation ($USD416.61K) is below average for companies of similar size in the US market ($USD3.31M).

Compensation vs Earnings: Yinxiang's compensation has been consistent with company performance over the past year.

CEO

Yinxiang Wang (60 yo)

less than a year
Tenure
CN¥2,900,000
Compensation

Dr. Yinxiang Wang serves as Consultant at Shining Capital. He is an Executive Chairman at Jacobio Pharmaceuticals Co. Ltd. since August 20, 2020.Dr. Wang has been Director at Jacobio Pharmaceuticals Co. L...

Leadership Team

NamePositionTenureCompensationOwnership
Yinxiang Wang
Founderless than a yearCN¥2.90m15.08%
$ 105.6m
Xiaojie Wang
Executive Director & President of Administration10.3yrsCN¥2.30m2.92%
$ 20.4m
Yunyan Hu
Executive VP & Executive Director6.8yrsCN¥2.47m2.96%
$ 20.7m
Andrea Wang-Gillam
Co-CEO, Executive VPless than a yearno datano data
Tao Yang
Vice President of Human Resourcesno datano datano data
Yanping Wang
Executive Vice President of Non-Clinical R&Dno datano datano data
Haijun Wang
Senior Vice President of Information & Data Managementno datano datano data
Yuli Ding
Executive Vice President of Clinical Developmentno datano datano data
Qing Xue
Joint Company Secretary5.4yrsno datano data
Ming Fai Chung
Joint Company Secretary3.4yrsno datano data
4.4yrs
Average Tenure
57.5yo
Average Age

Experienced Management: JBPH.F's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yinxiang Wang
Founder7.6yrsCN¥2.90m15.08%
$ 105.6m
Xiaojie Wang
Executive Director & President of Administration7.5yrsCN¥2.30m2.92%
$ 20.4m
Yunyan Hu
Executive VP & Executive Director7.5yrsCN¥2.47m2.96%
$ 20.7m
Ge Wu
Independent Non-Executive Director5.4yrsCN¥200.00kno data
Ruilin Song
Independent Non-Executive Director5.4yrsCN¥400.00kno data
Te-Li Chen
Non Executive Director5.4yrsno datano data
Bai Lu
Independent Non-Executive Director2.8yrsCN¥200.00kno data
5.4yrs
Average Tenure
60yo
Average Age

Experienced Board: JBPH.F's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/20 09:30
End of Day Share Price 2026/01/06 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jacobio Pharmaceuticals Group Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Linhai ZhaoGoldman Sachs